A prime-boost vaccination of mice with heterologous H5N1 strains

Vaccine

Volumn 27, Issue 23, 2009, Pages 3121-3125

  Ikeno, Daisuke ^a   Kimachi, Kazuhiko ^a   Kudo, Yasuhiro ^a   Goto, Shuro ^a   Itamura, Shigeyuki ^b   Odagiri, Takato ^b   Tashiro, Masato ^b   Kino, Yoichiro ^a  

^a Chemo Sero Therapeutic Research Institute   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Influenza; Pandemic; Prime boost vaccination

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; HEMAGGLUTININ; INFLUENZA VACCINE; NIBRG 14 VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SPECIFICITY; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INFLUENZA; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; SPECIES SPECIFICITY;

EID: 67349153350     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.007     Document Type: Article

References (23)

1. WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. http://www.who.int/csr/disease/avian_influenza/guidelines/H5VaccineVirusUpdate20080214.pdf. 2008.
2. WHO. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2007_12_09/en/index.html [accessed 09.12.2007].
3. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 January (4) (2005) 333-340
4. Normile D. Avian influenza. Human transmission but no pandemic in Indonesia. Science 312 June (5782) (2006) 1855
5. Wang H., Feng Z., Shu Y., Yu H., Zhou L., Zu R., et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 371 April (9622) (2008) 1427-1434
6. Yang Yang M.E.H., Sugimoto J., and Longini Jr. I.M. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis (2007) 13
7. Ministry of Health, Labour and Welfare in Japan, Pandemic Influenza and Avian Influenza. http://www.mhlw.go.jp/english/topics/influenza/index.html [accessed 11.02.2008].
8. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21 April (15) (2003) 1687-1693
9. Zangwill K.M., Treanor J.J., Campbell J.D., Noah D.L., and Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 197 February (4) (2008) 580-583
10. Goji N.A., Nolan C., Hill H., Wolff M., Noah D.L., Williams T.B., et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 198 September (5) (2008) 635-641
11. Ninomiya A., Imai M., Tashiro M., and Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25 May (18) (2007) 3554-3560
12. Stephenson I., Nicholson K.G., Gluck R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362 December (9400) (2003) 1959-1966
13. Gross P.A., Ennis F.A., Gaerlan P.F., Denson L.J., Denning C.R., and Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 136 November (5) (1977) 623-632
14. Parkman P.D., Hopps H.E., Rastogi S.C., and Meyer H.M. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 136 December (Suppl) (1977) S722-S730
15. Jennings R., Clark A., Oxford J.S., Hockley D.J., and Potter C.W. Reactogenicity and immunogenicity of whole and ether-Tween-split influenza A virus vaccines in volunteers. J Infect Dis 138 November (5) (1978) 577-586
16. Osterhaus A.D. Pre- or post-pandemic influenza vaccine?. Vaccine 25 June (27) (2007) 4983-4984
17. Wood J.M. Developing vaccines against pandemic influenza. Philos Trans R Soc Lond B Biol Sci 356 December (1416) (2001) 1953-1960
18. Bennink J., Effros R.B., and Doherty P.C. Influenzal pneumonia: early appearance of cross-reactive T cells in lungs of mice primed with heterologous type A viruses. Immunology 35 September (3) (1978) 503-509
19. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 September (9540) (2006) 991-997
20. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006 Mar) 1343-1351
21. Hovden A.O., Cox R.J., and Haaheim L.R. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol 62 July (1) (2005) 36-44
22. Sokolovska A., Hem S.L., and HogenEsch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 25 June (23) (2007) 4575-4585
23. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 12 August (4) (2000) 456-463